Core Insights - electroCore, Inc. announced a peer-reviewed study demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI) [1][2] - The study found that adjunctive use of gammaCore with standard care led to significant improvements in multiple domains of the Neurobehavioral Symptom Inventory (NSI) [2][4] - Approximately 34% of patients reported meaningful improvement in at least half of their persistent symptoms, with significant reductions observed in 16 of 22 symptom categories [8] Study Details - The study included 102 patients with persistent symptoms following mTBI, showing improvements in both early and late treatment groups [3][8] - No device-related adverse events were reported, indicating a favorable safety profile for the nVNS treatment [3] - The findings are particularly relevant for the U.S. military, where 1-2% of service members experience mild TBI annually [2] Company Overview - electroCore is a commercial-stage bioelectronic technology company focused on improving health through innovative non-invasive technologies [5] - The company's leading products include gammaCore nVNS and Quell neurostimulator, which treat chronic pain syndromes [5]